

# Media Release

ZURICH, SWITZERLAND – 30 MARCH 2011

---

## **The Annual General Meeting of Nobel Biocare approves all proposals of the Board of Directors**

Nobel Biocare Holding AG's Annual General Meeting today endorsed all proposals put forward by the Board of Directors.

Among others, the Annual General Meeting approved the allocation of reserves from capital contributions to free reserves to be used for a dividend of CHF 0.35 gross per registered share of CHF 0.40 nominal value. The dividend will be paid on 6 April 2011 (Ex-dividend day: 1 April 2011; record date: 5 April 2011).

The Board members proposed for reelection were re-elected: Daniela Bosshardt-Hengartner, Raymund Breu, Stig Eriksson, Edgar Fluri, Robert Lilja, Heino von Prondzynski, Oern Stuge and Rolf Watter.

According to the by-laws, all Board members have been elected for a one-year term.

At the first board meeting following the Annual General Meeting, Heino von Prondzynski was re-elected Chairman of the Board and Rolf Watter was re-elected Vice Chairman of the Board. Richard Laube will now take over as CEO as of 1 April 2011.

KPMG, Zurich, has been re-elected as auditors for the financial year 2011.

In 2012, the ordinary general meeting of the shareholders will be convened on 29 March at the same location (Swissôtel Zurich).

### Further information is available from:

**Media:**

Nicolas Weidmann  
Senior Vice President Global Communications  
Tel: +41 43 211 42 80, +41 79 372 29 81  
nicolas.weidmann@nobelbiocare.com

**Investors:**

Süha Demokan  
Head of Investor Relations  
Tel: +41 43 211 42 30, +41 79 430 81 46  
suha.demokan@nobelbiocare.com

### Financial reporting calendar 2011:

<b>Interim Report 1, 2011</b>	<b>28 April 2011</b>
<b>Interim Report 2, 2011</b>	<b>12 August 2011</b>
<b>Interim Report 3, 2011</b>	<b>8 November 2011</b>

**Disclaimer**

This media release contains forward-looking statements based on beliefs of Nobel Biocare's management. When used in this media release, words such as "anticipate", "believe", "estimate", "expect", "intend", "plan" and "project" are intended to identify forward-looking statements. They may involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nobel Biocare as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Nobel Biocare disclaims any intention or obligation to update these forward-looking statements.

---

**Nobel Biocare** (NOBN, SIX Swiss Exchange) is a world leader in innovative restorative and esthetic dental solutions. As a complete solutions provider, Nobel Biocare offers the most comprehensive range of solutions from tooth-to-root, for single tooth to edentulous indications. The solutions portfolio covers dental implants (including the key brands NobelActive™, Brånemark System® and NobelReplace™) as well as individualized prosthetics and equipment (NobelProcera™ guided surgery solutions and biomaterials). Nobel Biocare has more than 2,400 employees and recorded revenue of EUR 576.6 million in 2010. The company is headquartered in Zurich, Switzerland. Production takes place at seven sites located in Canada, Israel, Japan, Sweden, and the US. Nobel Biocare has 34 direct sales organizations.

---